Member Info for Aldebaran

MrIndia response proves this bored as lost all objectivity. You dont even know about it and alternative treatments that are cheaper, faster and less invasive. You dont want to know. You just want to log in, read that hemo is of to the moon and jack off all day happy.

There's more to making money than that. Other treatments such as mRNA are catching up and I do mean FAST. giving the vast somes you big time Charlie's claim to have here I am surprised your not more thorough in your research. Haywains comment about avacta having "ancient chemo" has been like a splinter in my mind. It proved to me he hasn't done his homework on avacta whatsoever yet was trying to trash it. How can I or we all be sure hes truly done his home work here then?

I dont doubt he understands autologous CAR-T but is he aware of emerging treatments, does he even bother to luck ? He is human after all and prone to bias and error making.

Do your own research monkeys

I was reading about a FLT3 specific allogenic CAR-T last night. Yes its a direct threat to hemo but its pre clinical.

Im surprised you dont know about it jhfh. This is why i say about having all your eggs in one basket is too risky. And I say vlad needs to get a move on

Haywain, what research have you done on autogenous CAR-T or mRNA treatments? Seem to me like these are much cheaper and better faster alternatives than autologous CAR-T ?

Have you actually looked at any other treatments and keeping up with competition? I ask that as a genuine quesiton because your comment about Avacta and "ancient chemo" really made me question your level of research. I do hope you haven't got the blinkers on here like these lot clearly have. A lot of people have outsourced there scientific due diligence to you by the looks of things

Saudi Arabian Refineries and Go Energy to develop Green Hydrogen Project - SaudiGulf Projects https://www.saudigulfprojects.com/2025/10/saudi-arabian-refineries-and-go-energy-to-develop-green-hydrogen-project/

Its a joke this. AFC are just not making the inroads needed to this market anywhere near quick enough.

2027 is the time to check in and see if their any sign of a turnaround

10x that. Confidence comes from the known clinical results for HG-CT-1. 3 out of 3 patience have seen excellent results. You should look at the statistical significance of that. These people have no other options and if this treatment gets approved it will be worth billions. Thats the bull case in a nutshell.

Price and valuation are not reflective of value here. You can prove that with a risk adjusted DCF calculation which ive previously done.

That being said, what's holding this back is poor communication from the company, lack of visibility on key milestones, better short term opportunities etc etc

I dunno cj. I don't bye into market makers game narrative. I reckon myles and his mates have all been selling there trading pots and pumping into mka. Now that is looking toppy and avacta have the conferences plus partner deal supposedly coming they'll be back here with there mka profits and start pumping this it is there way. Its just what they do and they have enough fire power and influence to make a difference

Don't start with the MM's playing games BS for fk sake. Their has been a seller simple as.

Selling as now slowed tho or stopped and with conferences imminent plus potential big pharma partner announcement coming alongside one of those (esmo most likely) then it doesn't take a rocket scientist to see what will happen to share price. It has already risen and built a base from which to spring off of .

Haywain, I think you are probably right about the science and you definitely seem to know your stuff about CAR-T & rr AML but you're totally off with your timelines and way market works etc.

Together, with the technicals you can put it all together and learn from each other to make better investment choices but instead the hemo ultras just cry about anything said other than tomorrow hemo is going to the moon. Shame but its to there detriment not mine.

Saint, I could go back through your rampy posts from years and find every time you said a stock was going up and wouldn't want to be out over weekend etc but I cba. You dont live in my head rent free like i appear to yours pmsl.

Haywain, you have been wrong with every single timeline prediction ever. It was you saying that there would be a big move after cohort 1 completed due to statistical improbability the results were anything other than conclusively proving the drug was working. You said that this isnt a solid tumours treatment and the big pharma boys would be all over this as the speed of clearance is all they need etc etc..

Were are they?

It was me that said Q1 2026 is when we might see some interest and now people are jumping on that as if it was there idea and belief originally.

At this rate though it won't even be Q1 and Vlad will need another placing. Investors, not traders but investors impartialcular instituons aren't going to buy in here with zero visibility on timelines.

Traders can trade this both ways up and down using price action only. Not releasing news timelines only hurts long term holders and puts off investors in my opinion but what do I know ive only been right about everything here 😅

Traders dont need news to trade stocks. They use price action and indicators so let's just clarify yet more nonsense from the hemo ultras.

Its not a raffle it is a investment. Should be any day now is ridiculous. Vlad should have laid out the timelines and have a roadmap for company over next 6 - 12 months. He's so lucky JHFH and his mates bailed him out otherwise all this good science would have no chance. I do wish he'd step aside and bring in a commercial driven, market savvy CEO to take hemo to the next steps. This is so poor its beyond depressing. Other small biotechs dont behave like this, it doesn't have to be like this but of course none of the HEMO ultras want to discus industry comparisons. They just want to log in, read some hugely bullish opinion about hemo that ends with go hemo go, then log out again.

Meanwhile company has lost almost half its value in the past few weeks. Unbelievable naievity for Vlad and the ultras not to have a plan to sustain value here

John is very credible, skin in the game and hes been there and got the t shirt.

Only problem is the timescale involved. He needs a couple of years and in that time AFC will be incinerating cash. Fast.

2027 will be a pivot point IMO.

Hi, I really dont know at the mo. I expected this to trade around 1000p until next bit of news within a range of 900p to 1200p. I'd be looking for a break of those levels either way with volume to confirm market direction.

I see 500p or 3000p both realistic next targets depending on what happens next

Who is dumping

Hemo is more of a religion than a investment. You have to buy without no visibility or timelines of major milestones and all the important trial data is supposedly owned by someone else who dont share it so we are kept in the dark and just need to have hope and faith.

It doesn't have to be like this. Other biotechs don't operate this way

Does anybody else see a wyn post and skip right over it or is it just me?

What a parasite this guy is. Highly recommend instead of getting into ANY kind of debate with him, just to ignore. Him.

John has already made it clear that nothing of any real significance until 2027. Even then you need to wait and see if it actually materialises in the accounts. I keep saying this John has said it and yet you all seem to be desperate for news to come ffs. They'll rebrand at some point, will announce who the S&P partner is (assuming deal hasn't broken down) and that's it. Neither will move share price in sustainable uptrend.

Needs sales. And a lot of them. 2027 will be the pivot point. Anything between now and then is wasted time and increasing likelihood of being caught in the next heavily discounted fundraise

If i was other technologies, such as what bicycle or filogen have and many other treatments I would be seriously worried about precision. For a start it is 10x cheaper than adc's...

Keytruda accounts for about 40% of merck sales. There valuation has been significantly hit since investors start becoming concerned about impending patent cliffs and merck were long seeking ways to replace that lost revenue.

Would not be surprised whatsoever to see we have partnered with them.

Any views on the bi-weekly dosing trials of ava6k ? Does that align with keytruda dosing of TNBC? who made that choice to go for 2 weekly dosing and why?

All to be revealed

Let's remember that 6103 has just overcome irinotecan resistance. Exetecan is 20x more potent though. No wonder Christina and the board are so excited. Its everything you could want in a investment this